Single-use Bioprocessing Systems Market, By Product Type (Bioreactors, Bags and Containers, Filtration Devices, Tubing Assemblies and Connectors, Sensors and Probes, Others), By Application (Monoclonal Antibody Production, Vaccine Production, Cell Therapy, Viral Vector Production, Gene Therapy, Other, Biopharmaceutical Production Processes), By End User (Biopharmaceutical Companies, CROs & CMOs, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa).

Published In : Feb 2024

Code : CMI1754

Pages :160

Formats :

Excel and PDF

Industry : Medical Devices

Single-use Bioprocessing Systems MarketSize and Trends

Global Single-use Bioprocessing Systems Market – Trends

Increasing outsourcing of bioproduction: The growing trend of outsourcing bioproduction processes to contract development and manufacturing organizations (CDMOs) has significantly impacted the global single-use bioprocessing systems market in recent years. More pharmaceutical and biotech companies are outsourcing their biomanufacturing needs to specialized CDMOs that offer flexible, cost-effective single-use technologies. This allows product developers to focus on their core competencies in R&D and reduces their capital investment in manufacturing infrastructure. CDMOs are increasingly adopting standardized, pre-validated single-use platforms that offer speed, flexibility, and aseptic safety. They can easily customize the processes as per client requirements and handle fluctuating production demands. This has enabled even small biotech startups and mid-sized firms to access large-scale biomanufacturing capabilities. For instance, many COVID-19 vaccine developers that lacked production facilities leveraged CDMOs to quickly scale-up using ready-to-use single-use systems. According to a 2021 report by the International Federation of Pharmaceutical Manufacturers & Associations, CDMOs accounted for 41% of the global vaccine production during the COVID-19 pandemic. As more biopharma companies opt to outsource, the demand for robust commercial-scale single-use solutions at CDMOs has surged significantly. Major elements of single-use bioprocessing infrastructure like bioreactors, mixers, tangential flow filtration devices, storage bags, and connectors are being rapidly added at several CDMO facilities. For example, Chinese CDMO WuXi Biologics has invested US$600 million since 2018 to expand its aseptic drug substance manufacturing capacity based on standardized perfusion-based single-use bioprocessing technologies, as stated on their corporate website. This has propelled overall sales of single-use systems among leading suppliers.